Products & Services · Total revenues
Livdelzi — Total revenues
Gilead Sciences Livdelzi — Total revenues increased by 232.5% to $133.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful market penetration, strong physician adoption, or effective commercial execution for this specific therapy, while a decrease may signal increased competition, loss of market share, or changes in patient access.
Detailed definition
This metric represents the total net sales generated from the commercialization of Livdelzi, a therapeutic product focus...
Peer comparison
Comparable to revenue metrics for specific specialty pharmaceutical assets or niche therapeutic products within the portfolios of other large-cap biopharmaceutical companies.
Metric ID:
gild_segment_livdelzi_total_revenuesHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $40.00M | $133.00M |
| QoQ Change | — | +232.5% |
| YoY Change | — | +232.5% |
Range$40.00M – $133.00M
Avg YoY Growth+232.5%
Median YoY Growth+232.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's livdelzi — total revenues?
- Gilead Sciences (GILD) reported livdelzi — total revenues of $133.00M in Q1 2026.
- What does livdelzi — total revenues mean?
- Total revenue generated from the sales of the liver disease medication Livdelzi.